These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29652308)

  • 1. [Clinical-psychopathological aspects of therapeutic effects of agomelatine (valdoxan) and its place in perfection of methods of therapy of postschizophrenic depressive disorders].
    Panteleyeva GP; Abramova LI; Novozhenova TE; Subbotskaya NV; Tikhonov DV; Yumatova PE; Nikiforova IY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(3):59-69. PubMed ID: 29652308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and therapeutic perspectives of agomelatine (valdoxan) in the treatment of anhedonia in patients with endogenous depressions].
    Panteleeva GP; Abramova LI; Oleichik IV; Omelchenko MA; Subbotskaya NV; Sorokin SA; Novozhenova TE; Nikiforova IY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(11):47-54. PubMed ID: 26978051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Agomelatine (valdoxan) in treatment of endogenous depression in day patient department].
    Chernova EV; Kozhechkina OV; Ter-Israelyan AY; Medvedev VE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10):43-46. PubMed ID: 27845315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experience of the antidepressive therapy with valdoxan (agomelatine) in a psychogeriatric unit of the psychiatric hospital].
    Kalyn YB; Safarova TP; Yakovleva OB; Sheshenin VS; Kornilov VV; Shipilova ES; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(11):55-62. PubMed ID: 26978052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The correlation of depressive and negative symptoms in the picture of post-schizophrenic depressions].
    Shumskaia KN
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(6):13-7. PubMed ID: 10441860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical experience with agomelatine for the treatment of depression in elderly patients in outpatient practice].
    Gavrilova SI; Kolykhalov IV; Ponomareva EV; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(9):43-8. PubMed ID: 25403300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical experience of the use of agomelatine in the treatment of patients with depression and chronic brain ischemia].
    Antonen EG; Nikitina MV; Kruchek MM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(12):79-85. PubMed ID: 26978498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder].
    Tiuvina NA; Smirnova VN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(11 Pt 2):53-60. PubMed ID: 23257757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The differences in the estimation of depression severity by psychiatrists and patients during the combined treatment with agomelatine (a multicenter study "EMOTSIA")].
    Medvedev VE; Retiunsky KY; Ovchinnikov AA; Barylnik YB; Shmilovich AA; Antokhin EY; Usov GM; Cheremin RA; Poletsky VM; Onegin AV; Kireeva IP; Frolova VI; Filippova NV; Antonova AA; Deeva MA; Onegina DA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11):26-34. PubMed ID: 28091498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of valdoxan in patients with irritable bowel syndrome].
    Balakina IV; Mironova TIa; Golovanova EN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(4):90-2. PubMed ID: 24874326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of depression with cognitive impairment].
    Medvedev VE; Ter-Israelyan AY; Frolova VI; Korovyakova EA; Gushanskaya EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(2):77-80. PubMed ID: 29560946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Valdoxan in the treatment of depression in neurological practice: results of the Russian multicenter naturalistic study "Resonance"].
    Vorob'eva OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9):47-51. PubMed ID: 23235412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The results of the Russian multicenter open observational non-comparative study on the efficacy and safety of valdoxan (agomelatin) in the treatment of patients with major depressive disorder and insomnia (the VIVALDI study)].
    Poluéktov MG; Levin YI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):39-44. PubMed ID: 24430033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An effect of valdoxan on the hemostasis in patients with acute coronary syndrome in the combination with anxiety and depressive disorders].
    Shimohina NY; Petrova MM; Savchenko AA; Piliugina MS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(2):30-36. PubMed ID: 26081321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.
    Englisch S; Jung HS; Lewien A; Becker A; Nowak U; Braun H; Thiem J; Eisenacher S; Meyer-Lindenberg A; Zink M
    J Clin Psychopharmacol; 2016 Dec; 36(6):597-607. PubMed ID: 27805978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of patients with moderate and severe nonpsychotic depressions].
    Zlokazova MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 1):30-2. PubMed ID: 21183920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.
    Emsley RA; Oosthuizen PP; Joubert AF; Roberts MC; Stein DJ
    J Clin Psychiatry; 1999 Nov; 60(11):747-51. PubMed ID: 10584762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, demographic and clinical features of comorbid depressive symptoms in drug naïve patients with schizophrenia presenting with first episode psychosis.
    Dai J; Du X; Yin G; Zhang Y; Xia H; Li X; Cassidy R; Tong Q; Chen D; Teixeira AL; Zheng Y; Ning Y; Soares JC; He MX; Zhang XY
    Schizophr Res; 2018 Mar; 193():182-187. PubMed ID: 28651908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Positive changes in the severity of residual psychotic symptoms in schizophrenic patients switched to treatment with risperidone].
    Burminskiy DS; Morozova MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(4):23-27. PubMed ID: 28617374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.